Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Information on Document Availability
19-Jul-2019 / 07:10 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Information on Document Availability
Aubagne, July 19, 2019 - The report on the first half 2019 results of
Sartorius Stedim Biotech Group (Paris: DIM) is now available at:
https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biote
ch-sa-investor-relations [1]
It contains the following information:
- Business development for the period of January to June 2019 as well as the
2019 full year forecast for the Sartorius Stedim Biotech Group
- Consolidated financial statements for the period ended June 30, 2019
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the
biopharmaceutical industry. As a total solutions provider, the company helps
its customers to manufacture biotech medications safely, rapidly and
economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is
quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D
sites in Europe, North America and Asia and an international network of sales
companies, Sartorius Stedim Biotech has a global reach. The Group has been
annually growing by double digits on average and has been regularly expanding
its portfolio by acquisitions of complementary technologies. In 2018, the
company earned sales revenue of EUR1,212.2 million and currently employs some
5,800 people.
Contact
Petra Kirchhoff; Head of Corporate Communications and Investor Relations
Phone: +49(0)551.308.1686; petra.kirchhoff@sartorius.com
Regulatory filing PDF file
Document title: Information on Document Availability
Document: http://n.eqs.com/c/fncls.ssp?u=UMBRBLJRIL [2]
Language: English
Company: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: info@sartorius-stedim.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
Euronext Ticker: DIM
AMF Category: Half-yearly financial and audit reports/reduced exams /
Terms of availability of the half-yearly financial report
EQS News ID: 843751
End of Announcement EQS News Service
843751 19-Jul-2019 CET/CEST
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=6c2d28e59a2bbaf6c800dee64704a280&application_id=843751&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=638b8aba3b6a0fbdf097c18d25b75cd8&application_id=843751&site_id=vwd&application_name=news
(END) Dow Jones Newswires
July 19, 2019 01:10 ET (05:10 GMT)
© 2019 Dow Jones News
